Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study.

Int J Chron Obstruct Pulmon Dis · 2018 · PMC5909796 · PMID 29713156

Europe PMC DOI

hedged sentence

0.0642

closest p · 1.3× alpha

0.0642

boldest claim

The sentences

did not reach statistical significanceP =0.0642so close (0.05 < p ≤ 0.1)

Risk of CID was also reduced by IND/GLY using definitions D1 and D2; however, these differences did not reach statistical significance (D1: OR, 0.76 [95% CI: 0.56–1.02]; P =0.0642; D2: OR, 0.75 [95% CI: 0.56–1.00]; P =0.0529; Figure 3 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.